

47. (New) An isolated antibody that binds specifically to the polypeptide of claim 42.

48. (New) An isolated antibody that binds specifically to a polypeptide of claim 43.

REMARKS

With entry of this Preliminary Amendment, claims 4, 5 and 16-47 are pending in this application. New claims 42 and 43 are supported by original claims 1-3 and in the specification at least at page 8, lines 22-25 (claim 42) and page 15, lines 11-14 (claim 43). Claims 44-48 are supported in the specification at least at page 8, lines 7-10 and page 12, lines 11-31 (claims 44-46) and page 31, lines 6-11 (claims 47 and 48). No new matter is added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**"

All of the claims remaining in the application are now clearly allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.




00500

PATENT TRADEMARK OFFICE

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E. R. Potter

Registration No. 33,332

(JEP:cew) #251222

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph beginning at line 4 of page 7 has been amended as follows:

Figure 3. Alignment of related proteins *scBUB3*, *muBUB3*, *huBUB3* (2.7), *hu-rae1*, *rae-1* (*Schizosaccharomyces pombe*), *scYET7*, *scBUB3*, *hu-rae1*, *sp-rae1* and *scYET7* sequences were obtained from Genbank. The murine sequence is derived from Genbank entry U67327, corrected using overlapping murine EST entries for a reading frame error which truncated the predicted reading frame at the [N-terminus] C-terminus. Predicted WD40 repeat regions are indicated with roman numerals. Conserved residues are indicated below the alignments.

In the Claims:

Claims 1-3 and 6-15 have been canceled.

New claims 42-48 have been added.

(JEP:cew) #251222